The Prospect of Biomimetic Immune Cell Membrane-Coated Nanomedicines for Treatment of Serious Bacterial Infections and Sepsis

J Pharmacol Exp Ther. 2024 Apr 5:JPET-MR-2023-002095. doi: 10.1124/jpet.123.002095. Online ahead of print.

Abstract

Invasive bacterial infections and sepsis are persistent global health concerns, complicated further by the escalating threat of antibiotic resistance. Over the past 40 years, collaborative endeavors to improve the diagnosis and critical care of septic patients have improved outcomes, yet grappling with the intricate immune dysfunction underlying the septic condition remains a formidable challenge. Anti-inflammatory interventions that exhibited promise in murine models failed to manifest consistent survival benefits in clinical studies through recent decades. Novel therapeutic approaches that target bacterial virulence factors, for example with monoclonal antibodies, aim to thwart pathogen-driven damage and restore an advantage to the immune system. A pioneering technology addressing this challenge is biomimetic nanoparticles-a therapeutic platform featuring nanoscale particles enveloped in natural cell membranes. Borne from the quest for a durable drug delivery system, the original red blood cell-coated nanoparticles showcased a broad capacity to absorb bacterial and environmental toxins from serum. Tailoring the membrane coating to immune cell sources imparts unique characteristics to the nanoparticles suitable for broader application in infectious disease. Their capacity to bind both inflammatory signals and virulence factors assembles the most promising sepsis therapies into a singular, pathogen-agnostic therapeutic. This review explores the ongoing work on immune cell-coated nanoparticle therapeutics for infection and sepsis. Significance Statement In the quest to combat antibiotic-resistant bacterial infections and sepsis, an innovative approach has emerged in which nanoscale particles are enveloped in natural cell membranes purified from human blood cells. Since this technology shows the ability to (a) neutralize bacterial toxins that injure host cells and (b) quell the exaggerated septic inflammation that leads to deadly organ system failure, these novel nanomedicines may represent a versatile strategy to complement antibiotics and vaccines in the ongoing battle against infectious diseases.

Keywords: Nanoparticles; bacterial infections; cytokines; macrophages; membrane-protein interactions; septic shock.